Einfluß einer supplementären Therapie mit postprandial injiziertem Insulin Lispro (Huma-log®) auf diabetesbezogene Komplikationen und Lebensqualität bei geriatrischen Patienten mit Typ 2 Diabetes

Profil Institut fuer Stoffwechselforschung GmbH0 个研究点目标入组 104 人开始时间: 2004年10月18日最近更新: 2020年2月1日

适应症

试验速览

暂无简介。

•- type 2 diabetes
•- age 70 years or above
•- HbA1c 6-12% (inclusive)
•- insulin therapy with twice daily injections of a premixed insulin for at least 3 months
•- able to give written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- significant cardiovascular event (e.g. myocardial infarction, stroke) in the past 6 months
•- presence of a disease which might influence the study results or involves an additional risk for study participation for the subjects
•- clinically relevant deviations in lab parameters from normal (e.g. liver enzymes more than threefold above upper limit of normal, serum creatinine higher than 1.7 mg/dl
•- concomitant medication which might influence the study results (e.g. steroids)
•- alcohol or drug addiction
•- inability to understand the informed consent or the study procedures
•- participation in another trial in the past 4 weeks

发起方

Profil Institut fuer Stoffwechselforschung GmbH